Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review

Diabetic macular edema (DMO) is a leading cause of blindness in the working age population. Although anti-vascular endothelial growth factor (VEGF) therapy provided a major advance in treatment of DMO for many patients, there is a significant proportion of patients who maintain persistent DMO and ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Fusi-Rubiano, William, Blow, Rebecca R., Lane, Mark, Morjaria, Rupal, Denniston, Alastair K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258573/
https://www.ncbi.nlm.nih.gov/pubmed/30229441
http://dx.doi.org/10.1007/s40123-018-0145-7
_version_ 1783374523189428224
author Fusi-Rubiano, William
Blow, Rebecca R.
Lane, Mark
Morjaria, Rupal
Denniston, Alastair K.
author_facet Fusi-Rubiano, William
Blow, Rebecca R.
Lane, Mark
Morjaria, Rupal
Denniston, Alastair K.
author_sort Fusi-Rubiano, William
collection PubMed
description Diabetic macular edema (DMO) is a leading cause of blindness in the working age population. Although anti-vascular endothelial growth factor (VEGF) therapy provided a major advance in treatment of DMO for many patients, there is a significant proportion of patients who maintain persistent DMO and have minimal response to anti-VEGF treatment. Iluvien (fluocinolone acetonide 0.19 mg [FAc]) is an important additional treatment option for DMO. In this review we describe the clinical context and the evidence for the use of the FAc implant in treating DMO, from pilot to randomized controlled studies, to later phase real world data. These studies indicate that the FAc implant is effective, well tolerated and a cost-effective option in the treatment of insufficiently responsive DMO.
format Online
Article
Text
id pubmed-6258573
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-62585732018-12-11 Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review Fusi-Rubiano, William Blow, Rebecca R. Lane, Mark Morjaria, Rupal Denniston, Alastair K. Ophthalmol Ther Review Diabetic macular edema (DMO) is a leading cause of blindness in the working age population. Although anti-vascular endothelial growth factor (VEGF) therapy provided a major advance in treatment of DMO for many patients, there is a significant proportion of patients who maintain persistent DMO and have minimal response to anti-VEGF treatment. Iluvien (fluocinolone acetonide 0.19 mg [FAc]) is an important additional treatment option for DMO. In this review we describe the clinical context and the evidence for the use of the FAc implant in treating DMO, from pilot to randomized controlled studies, to later phase real world data. These studies indicate that the FAc implant is effective, well tolerated and a cost-effective option in the treatment of insufficiently responsive DMO. Springer Healthcare 2018-09-18 2018-12 /pmc/articles/PMC6258573/ /pubmed/30229441 http://dx.doi.org/10.1007/s40123-018-0145-7 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Fusi-Rubiano, William
Blow, Rebecca R.
Lane, Mark
Morjaria, Rupal
Denniston, Alastair K.
Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
title Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
title_full Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
title_fullStr Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
title_full_unstemmed Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
title_short Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
title_sort iluvien™ (fluocinolone acetonide 0.19 mg intravitreal implant) in the treatment of diabetic macular edema: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258573/
https://www.ncbi.nlm.nih.gov/pubmed/30229441
http://dx.doi.org/10.1007/s40123-018-0145-7
work_keys_str_mv AT fusirubianowilliam iluvienfluocinoloneacetonide019mgintravitrealimplantinthetreatmentofdiabeticmacularedemaareview
AT blowrebeccar iluvienfluocinoloneacetonide019mgintravitrealimplantinthetreatmentofdiabeticmacularedemaareview
AT lanemark iluvienfluocinoloneacetonide019mgintravitrealimplantinthetreatmentofdiabeticmacularedemaareview
AT morjariarupal iluvienfluocinoloneacetonide019mgintravitrealimplantinthetreatmentofdiabeticmacularedemaareview
AT dennistonalastairk iluvienfluocinoloneacetonide019mgintravitrealimplantinthetreatmentofdiabeticmacularedemaareview

Ejemplares similares